EZH2 and cancer: This apparent discrepancy might rely on variations of EZH2 activity in the different loss of function systems: while in our experiments and previous reports in breast [15, 16] and lung [6–8] cancer the function of EZH2 was assayed in systems in which EZH2 protein level was reduced to undetectable levels, EED-depleted HMLER cells display only partial downregulation of EZH2 protein [9].